USD 0.03
(258.67%)
Year | Inventory | Inventory Growth |
---|---|---|
2024 | - CAD | -100.0% |
2023 | 40 Thousand CAD | 0.0% |
2022 | 40 Thousand CAD | 120.42% |
2021 | -195.9 Thousand CAD | 0.0% |
2020 | - CAD | 0.0% |
2019 | - CAD | 0.0% |
2018 | - CAD | 0.0% |
2017 | - CAD | 0.0% |
2016 | - CAD | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 FY | - CAD | -100.0% |
2024 Q4 | - CAD | -100.0% |
2024 Q1 | - CAD | -100.0% |
2024 Q3 | 1.00 CAD | 0.0% |
2024 Q2 | - CAD | 0.0% |
2023 Q2 | 45.22 Thousand CAD | 0.0% |
2023 FY | 40 Thousand CAD | 0.0% |
2023 Q4 | 147.47 Thousand CAD | 226.07% |
2023 Q3 | 45.22 Thousand CAD | 0.0% |
2023 Q1 | 45.22 Thousand CAD | 13.07% |
2022 Q3 | 37.17 Thousand CAD | -5.38% |
2022 FY | 40 Thousand CAD | 120.42% |
2022 Q1 | 5000.00 CAD | 0.0% |
2022 Q4 | 40 Thousand CAD | 7.59% |
2022 Q2 | 39.29 Thousand CAD | 685.84% |
2021 Q2 | - CAD | 0.0% |
2021 FY | -195.9 Thousand CAD | 0.0% |
2021 Q4 | - CAD | 0.0% |
2021 Q3 | - CAD | 0.0% |
2020 FY | - CAD | 0.0% |
2019 FY | - CAD | 0.0% |
2018 FY | - CAD | 0.0% |
2017 FY | - CAD | 0.0% |
2016 FY | - CAD | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
AstraZeneca PLC | 5.41 Billion USD | 100.0% |
Bristol-Myers Squibb Company PFD CONV 2 | 2.66 Billion USD | 100.0% |
CSPC Pharmaceutical Group Limited | 442.43 Million USD | 100.0% |
Clarus Therapeutics Holdings, Inc. | 14.21 Million USD | 100.0% |
Novartis AG | 5.91 Billion USD | 100.0% |
PT Kalbe Farma Tbk. | 451.27 Million USD | 100.0% |